Publication of OIG Special Fraud Alerts, 51683-51687 [2022-18063]
Download as PDF
Federal Register / Vol. 87, No. 162 / Tuesday, August 23, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2022–N–1778 for ‘‘Endocrinologic and
Metabolic Drugs Advisory Committee;
Notice of Meeting; Establishment of a
Public Docket; Request for Comments.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ FDA
will review this copy, including the
claimed confidential information, in its
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify the information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
VerDate Sep<11>2014
18:53 Aug 22, 2022
Jkt 256001
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
LaToya Bonner, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–2855, Fax: 301–847–8533, email:
EMDAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
FDA’s website at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. The
committee will discuss new drug
application (NDA) 215559, for
palovarotene capsules, submitted by
Ipsen Biopharmaceuticals, Inc. The
proposed indication is the prevention of
heterotopic ossification in adults and
children (females aged 8 years and
above and males 10 years and above)
with fibrodysplasia ossificans
progressiva.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available on FDA’s
website at the time of the advisory
committee meeting. Background
material and the link to the online
teleconference meeting room will be
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link. The meeting will include slide
presentations with audio components to
allow the presentation of materials in a
manner that most closely resembles an
in-person advisory committee meeting.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
51683
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see ADDRESSES) on or before
October 17, 2022, will be provided to
the committee. Oral presentations from
the public will be scheduled between
approximately 1:30 p.m. and 2:30 p.m.
eastern time. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before October
6, 2022. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by October 7, 2022.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact LaToya Bonner
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 17, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–18143 Filed 8–22–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
Publication of OIG Special Fraud Alerts
Office of Inspector General
(OIG), HHS.
AGENCY:
E:\FR\FM\23AUN1.SGM
23AUN1
51684
ACTION:
Federal Register / Vol. 87, No. 162 / Tuesday, August 23, 2022 / Notices
Notice.
This Federal Register notice
sets forth two Special Fraud Alerts
previously published by OIG on its
website. We are publishing these
Special Fraud Alerts in the Federal
Register to ensure widespread
dissemination of the Special Fraud
Alerts to the general public and to
satisfy the Federal Register publication
requirement.
FOR FURTHER INFORMATION CONTACT:
Katie Fink, Karen Glassman, or
Benjamin Wallfisch, (202) 619–0335.
SUMMARY:
I. Background
Pursuant to 42 U.S.C. 1320a–7d(c),
OIG periodically issues Special Fraud
Alerts to give continuing guidance to
health care industry stakeholders
regarding practices OIG considers to be
suspect or of particular concern. Special
Fraud Alerts encourage industry
compliance by giving stakeholders
guidance that can be applied to their
own practices. In developing Special
Fraud Alerts, OIG relies on several
sources and consults directly with
experts in the subject field including
those within OIG, other HHS agencies,
other Federal and State agencies, and in
the health care industry.
To ensure widespread dissemination
of this information to the general public
and to satisfy the Federal Register
publication requirement found in 42
U.S.C. 1320a–7d(c)(1)(B), OIG is
republishing two Special Fraud Alerts—
in their entirety—below. These Special
Fraud Alerts are: (1) Special Fraud
Alert: Speaker Programs, which was
originally published on OIG’s website
on November 16, 2020; and (2) Special
Fraud Alert: OIG Alerts Practitioners To
Exercise Caution When Entering Into
Arrangements With Purported
Telemedicine Companies, which was
originally published on OIG’s website
on July 20, 2022.
lotter on DSK11XQN23PROD with NOTICES1
II. Special Fraud Alert: Speaker
Programs
I. Introduction
This Special Fraud Alert highlights
the fraud and abuse risks associated
with the offer, payment, solicitation, or
receipt of remuneration relating to
speaker programs by pharmaceutical
and medical device companies. For
purposes of this Special Fraud Alert,
speaker programs are generally defined
as company-sponsored events at which
a physician or other health care
professional (collectively, ‘‘HCP’’)
makes a speech or presentation to other
HCPs about a drug or device product or
a disease state on behalf of the
company. The company generally pays
VerDate Sep<11>2014
18:53 Aug 22, 2022
Jkt 256001
the speaker HCP an honorarium, and
often pays remuneration (for example,
free meals) to the attendees. In the last
three years, drug and device companies
have reported paying nearly $2 billion
to HCPs for speaker-related services.1
The Office of Inspector General (OIG)
and Department of Justice (DOJ) have
investigated and resolved numerous
fraud cases involving allegations that
remuneration offered and paid in
connection with speaker programs
violated the anti-kickback statute. The
Federal government has pursued civil
and criminal cases against companies
and individual HCPs involving speaker
programs. These cases alleged, for
example, that drug and device
companies:
• selected high-prescribing HCPs to
be speakers and rewarded them with
lucrative speaker deals (e.g., some HCPs
received hundreds of thousands of
dollars for speaking); 2
• conditioned speaker remuneration
on sales targets (e.g., required speaker
HCPs to write a minimum number of
prescriptions in order to receive the
speaker honoraria);
• held speaker programs at
entertainment venues or during
recreational events or otherwise in a
manner not conducive to an educational
presentation (e.g., wineries, sports
stadiums, fishing trips, golf clubs, and
adult entertainment facilities);
• held programs at high-end
restaurants where expensive meals and
alcohol were served (e.g., in one case,
the average food and alcohol cost per
attendee was over $500); and
• invited an audience of HCP
attendees who had previously attended
the same program or HCPs’ friends,
significant others, or family members
who did not have a legitimate business
reason to attend the program.
Our enforcement experience
demonstrates that some companies
expend significant resources on speaker
programs and that some HCPs receive
substantial remuneration from
1 Drug and device companies are required to
report certain payments made to HCPs to the
Centers for Medicare & Medicaid Services (CMS).
CMS makes this information publicly available on
its Open Payments website. According to Open
Payments, drug and device companies paid HCPs
nearly $2 billion under the category ‘‘compensation
for services other than consulting, including serving
as faculty or as a speaker at a venue other than a
continuing education program’’ for years 2017,
2018, and 2019 combined. Open Payments
Complete 2017, 2018, and 2019 Program Year
Datasets, CMS, https://www.cms.gov/
OpenPayments/Explore-the-Data/Data-Overview
(accessed Sept. 9, 2020).
2 Though not addressed in this Special Fraud
Alert, remuneration paid by drug and device
companies relating to the training of HCP speakers
also may raise fraud and abuse risks.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
companies. This Special Fraud Alert
highlights some of the inherent fraud
and abuse risks associated with the
offer, payment, solicitation, or receipt of
remuneration related to companysponsored speaker programs.
II. The Anti-Kickback Statute
Congress enacted the anti-kickback
statute, in part, to protect patients from
referrals or recommendations by HCPs
who may be influenced by
inappropriate financial incentives. The
anti-kickback statute makes it a criminal
offense to knowingly and willfully
solicit, receive, offer, or pay any
remuneration to induce or reward,
among other things, referrals for, or
orders of, items or services reimbursable
by a Federal health care program.3
When remuneration is paid
purposefully to induce or reward
referrals of items or services payable by
a Federal health care program, the antikickback statute is violated. For
purposes of the anti-kickback statute,
the offer, payment, solicitation, or
receipt of ‘‘remuneration’’ includes the
transfer of anything of value, directly or
indirectly, overtly or covertly, in cash or
in kind. By its terms, the statute ascribes
criminal liability to all parties to an
impermissible ‘‘kickback’’ transaction
(i.e., those who solicit or receive
prohibited remuneration as well as
those who offer or pay the prohibited
remuneration). Violation of the statute is
a felony punishable by a maximum fine
of $100,000, imprisonment up to 10
years, or both. Criminal conviction will
also lead to mandatory exclusion from
Federal health care programs, including
Medicare and Medicaid.4 OIG may also
initiate administrative proceedings to
exclude persons from the Federal health
care programs and impose civil money
penalties for conduct prohibited by the
anti-kickback statute.5
III. Fraud and Abuse Risks of Speaker
Programs
Numerous investigations have
involved allegations that drug and
device companies organize and pay for
speaker programs with the intent to
3 See section 1128B(b)(1)–(2) of the Social
Security Act; 42 U.S.C. 1320a–7b(b)(1)–(2). The
anti-kickback statute applies broadly to
remuneration to induce or reward referrals of
patients as well as the payment of remuneration
intended to induce or reward the purchasing,
leasing, or ordering of, or arranging for or
recommending the purchasing, leasing, or ordering
of, any item or service reimbursable by any Federal
health care program. In this Special Fraud Alert, we
use the term ‘‘referral’’ to include the full range of
these types of activities (including ordering or
prescribing items) that falls within the scope of the
anti-kickback statute.
4 See 42 U.S.C. 1320a–7(a).
5 See 42 U.S.C. 1320a–7(b)(7); 1320a–7a(a)(7).
E:\FR\FM\23AUN1.SGM
23AUN1
Federal Register / Vol. 87, No. 162 / Tuesday, August 23, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
induce HCPs to prescribe or order (or
recommend the prescription or ordering
of) the companies’ products. Speaker
programs typically involve an HCP who
is not an employee of the company
speaking in person to other HCPs about
a company product or disease state
using a presentation developed and
approved by the company. According to
a pharmaceutical industry trade group,
HCPs ‘‘participate in companysponsored speaker programs in order to
help educate and inform other health
care professionals about the benefits,
risks, and appropriate uses of company
medicines.’’ 6
OIG is skeptical about the educational
value of such programs. Our
investigations have revealed that, often,
HCPs receive generous compensation to
speak at programs offered under
circumstances that are not conducive to
learning or to speak to audience
members who have no legitimate reason
to attend. Such cases strongly suggest
that one purpose of the remuneration to
the HCP speaker and attendees is to
induce or reward referrals. Furthermore,
studies have shown that HCPs who
receive remuneration from a company
are more likely to prescribe or order that
company’s products.7 This
remuneration to HCPs may skew their
clinical decision making in favor of
their own and the company’s financial
interests, rather than the patient’s best
interests.
There are many other ways for HCPs
to obtain information about drug and
device products and disease states that
do not involve remuneration to HCPs.
HCPs can access the same or similar
information provided in a speaker
program using various online resources,
the product’s package insert, third-party
educational conferences, medical
journals, and more. The availability of
this information through means that do
not involve remuneration to HCPs
further suggests that at least one
6 Code on Interactions with Health Care
Professionals, PhRMA, 7 (June 2020), available at
https://phrma.org/Codes-and-guidelines/Code-onInteractions-with-Health-Care-Professionals. A
device industry trade group also addresses this
topic and interactions with HCPs generally in its
code of ethics. See AdvaMed Code of Ethics,
AdvaMed (July 2020), available at https://
www.advamed.org/resource-center/advamed-codeethics-2020.
7 Amarnath Annapureddy et al., Association
Between Industry Payments to Physicians and
Device Selection in ICD Implantation, 324 JAMA 17,
2020, at 1759, 1762–63; William Fleischman et al.,
Association between payments from manufacturers
of pharmaceuticals to physicians and regional
prescribing: cross sectional ecological study, 354
BMJ i4189, 2016, at 1, 4–7; James P. Orlowski &
Leon Wateska, The effects of pharmaceutical firm
enticements on physician prescribing patterns.
There’s no such thing as a free lunch., 102 Chest,
1992, 270.
VerDate Sep<11>2014
18:53 Aug 22, 2022
Jkt 256001
purpose of remuneration associated
with speaker programs is often to
induce or reward referrals.
Parties involved in speaker programs
may be subject to increased scrutiny.
These include any drug or device
company that organizes or pays
remuneration associated with the
program, any HCP who is paid to speak,
and any HCP attendees who receive
remuneration from the company (e.g.,
free food and drink). OIG has long
expressed concerns over the practice of
drug and device companies providing
anything of value to HCPs in a position
to make or influence referrals to such
companies’ products. In the 2003 OIG
Compliance Program Guidance for
Pharmaceutical Manufacturers,8 OIG
identified manufacturer compensation
relationships with physicians connected
directly or indirectly to marketing and
sales activities, including speaking
activities, as an area of potential risk
under the anti-kickback statute. OIG
noted that when a drug or device
company engages in ‘‘entertainment,
recreation, travel, meals or other
benefits in association with information
or marketing presentations,’’ such
arrangements may potentially implicate
the anti-kickback statute.9
OIG also warned physicians that a
consultant or speaking arrangement
with a drug or device company could be
an improper inducement ‘‘to prescribe
or use [company] products on the basis
of . . . loyalty to the company or to get
more money from the company, rather
than because it is the best treatment for
the patient.’’ 10 OIG recommended that
physicians consider the propriety of any
proposed relationship with a company
and advised that if the basis for a
physician’s compensation ‘‘is your
ability to prescribe a drug or use a
medical device or refer your patients for
particular services or supplies, the
proposed consulting arrangement likely
is one you should avoid as it could
8 OIG Compliance Program Guidance for
Pharmaceutical Manufacturers, 68 FR 23731 (May
5, 2003), available at https://oig.hhs.gov/authorities/
docs/03/050503FRCPGPharmac.pdf. The guidance
is not limited to pharmaceutical manufacturers; it
states, ‘‘the compliance program elements and
potential risk areas addressed in this compliance
program guidance may also have application to
manufacturers of other products that may be
reimbursed by [F]ederal health care programs, such
as medical devices and infant nutritional products.’’
Id. at 23742, n.5.
9 Id. at 23738.
10 A Roadmap for New Physicians, Avoiding
Medicare and Medicaid Fraud and Abuse, HHS–
OIG, 22 (Nov. 2010), available at https://
oig.hhs.gov/compliance/physician-education/
roadmap_web_version.pdf; OIG Compliance
Program for Individual and Small Group Physician
Practices, 65 FR 59434 (Oct. 5, 2000), available at
https://oig.hhs.gov/authorities/docs/physician.pdf.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
51685
violate fraud and abuse laws.’’ 11 Again,
we note that HCPs could face liability
under the anti-kickback statute for
knowingly and willfully soliciting or
receiving remuneration in connection
with speaker programs in return for
prescribing or ordering products
reimbursable by a Federal health care
program.
OIG recognizes that the lawfulness of
any remunerative arrangement,
including speaker program
arrangements, under the anti-kickback
statute depends on the facts and
circumstances and intent of the parties.
Such intent may be evidenced by the
speaker program’s characteristics and
the actual conduct of the parties
involved. Below we describe some
characteristics, which, taken separately
or together, potentially indicate a
speaker program arrangement that could
violate the anti-kickback statute. As
previously stated, drug and device
companies that host or pay for such
speaker programs and HCPs who speak
at or attend such programs could be
liable under the anti-kickback statute for
any prohibited remuneration. This list
of suspect characteristics is illustrative,
not exhaustive, and the presence or
absence of any one of these factors is not
determinative of whether a particular
arrangement would be suspect under
the anti-kickback statute.
• The company sponsors speaker
programs where little or no substantive
information is actually presented;
• Alcohol is available or a meal
exceeding modest value is provided to
the attendees of the program (the
concern is heightened when the alcohol
is free);
• The program is held at a location
that is not conducive to the exchange of
educational information (e.g.,
restaurants or entertainment or sports
venues);
• The company sponsors a large
number of programs on the same or
substantially the same topic or product,
especially in situations involving no
recent substantive change in relevant
information;
• There has been a significant period
of time with no new medical or
scientific information nor a new FDAapproved or cleared indication for the
product;
• HCPs attend programs on the same
or substantially the same topics more
than once (as either a repeat attendee or
as an attendee after being a speaker on
the same or substantially the same
topic);
• Attendees include individuals who
don’t have a legitimate business reason
11 Id.
E:\FR\FM\23AUN1.SGM
at 23.
23AUN1
51686
Federal Register / Vol. 87, No. 162 / Tuesday, August 23, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
to attend the program, including, for
example, friends, significant others, or
family members of the speaker or HCP
attendee; employees or medical
professionals who are members of the
speaker’s own medical practice; staff of
facilities for which the speaker is a
medical director; and other individuals
with no use for the information;
• The company’s sales or marketing
business units influence the selection of
speakers or the company selects HCP
speakers or attendees based on past or
expected revenue that the speakers or
attendees have or will generate by
prescribing or ordering the company’s
product(s) (e.g., a return on investment
analysis is considered in identifying
participants);
• The company pays HCP speakers
more than fair market value for the
speaking service or pays compensation
that takes into account the volume or
value of past business generated or
potential future business generated by
the HCPs.
IV. Conclusion
OIG has significant concerns about
companies offering or paying
remuneration (and HCPs soliciting or
receiving remuneration) in connection
with speaker programs. Based on our
investigations and enforcement actions,
this remuneration is often offered or
paid to induce (or solicited or received
in return for) ordering or prescribing
items paid for by Federal health care
programs. If the requisite intent is
present, both the company and the
HCPs may be subject to criminal, civil,
and administrative enforcement actions.
This Special Fraud Alert is not intended
to discourage meaningful HCP training
and education. Rather, the purpose of
this Special Fraud Alert is to highlight
certain inherent risks of remuneration
related to speaker programs. Drug and
device companies and HCPs should
consider the risks when assessing
whether to offer, pay, solicit, or receive
remuneration related to speaker
programs.
We are issuing this alert during the
pandemic emergency, which is
necessarily curtailing many in-person
activities. While companies may have
decreased in-person speaker programrelated remuneration to HCPs during the
pandemic, risks remain whenever
payments are offered or made to HCPs
who generate Federal health care
program business for the company. The
risks associated with speaker programs
will become more pronounced if
companies resume in-person speaker
programs or increase speaker programrelated remuneration to HCPs.
Companies should assess the need for
VerDate Sep<11>2014
18:53 Aug 22, 2022
Jkt 256001
in-person programs given the risks
associated with offering or paying
related remuneration and consider
alternative less-risky means for
conveying information to HCPs. HCPs
should likewise consider the risks of
soliciting or receiving remuneration
related to speaker programs given other
available means to gather information
relevant to providing appropriate
treatment for patients. If a company or
HCP has questions about a specific
speaker program arrangement involving
remuneration to referral sources, the
OIG Advisory Opinion process remains
available. Information about that
process may be found at: https://
oig.hhs.gov/faqs/advisory-opinionsfaq.asp.
III. Special Fraud Alert: OIG Alerts
Practitioners To Exercise Caution When
Entering Into Arrangements With
Purported Telemedicine Companies
I. Introduction
The Office of Inspector General (OIG)
has conducted dozens of investigations
of fraud schemes involving companies
that purported to provide telehealth,
telemedicine, or telemarketing services
(collectively, Telemedicine Companies)
and exploited the growing acceptance
and use of telehealth. For example, in
some of these fraud schemes
Telemedicine Companies intentionally
paid physicians and nonphysician
practitioners (collectively, Practitioners)
kickbacks to generate orders or
prescriptions for medically unnecessary
durable medical equipment, genetic
testing, wound care items, or
prescription medications, resulting in
submissions of fraudulent claims to
Medicare, Medicaid, and other Federal
health care programs. These fraud
schemes vary in design and operation,
and they have involved a wide range of
different individuals and types of
entities, including international and
domestic telemarketing call centers,
staffing companies, Practitioners,
marketers, brokers, and others.
One common element of these
schemes is the way Telemedicine
Companies have used kickbacks to
aggressively recruit and reward
Practitioners to further the fraud
schemes. Generally, the Telemedicine
Companies arrange with Practitioners to
order or prescribe medically
unnecessary items and services for
individuals (referred to here as
‘‘purported patients’’) who are solicited
and recruited by Telemedicine
Companies. In many of these
arrangements, Telemedicine Companies
pay Practitioners in exchange for
ordering or prescribing items or
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
services: (1) for purported patients with
whom the Practitioners have limited, if
any, interaction; and (2) without regard
to medical necessity. Such payments are
sometimes described as payment per
review, audit, consult, or assessment of
medical charts. Telemedicine
Companies often tell Practitioners that
they do not need to contact the
purported patient or that they only need
speak to the purported patient by
telephone. In addition, Practitioners are
not given an opportunity to review the
purported patient’s real medical
records. Furthermore, the Telemedicine
Company may direct Practitioners to
order or prescribe a preselected item or
service, regardless of medical necessity
or clinical appropriateness. In many
cases, the Telemedicine Company sells
the order or prescription generated by
Practitioners to other individuals or
entities that then fraudulently bill for
the unnecessary items and services.
These schemes raise fraud concerns
because of the potential for considerable
harm to Federal health care programs
and their beneficiaries, which may
include: (1) an inappropriate increase in
costs to Federal health care programs for
medically unnecessary items and
services and, in some instances, items
and services a beneficiary never
receives; (2) potential to harm
beneficiaries by, for example, providing
medically unnecessary care, items that
could harm a patient, or improperly
delaying needed care; and (3) corruption
of medical decision-making.
OIG encourages Practitioners to
exercise caution and use heightened
scrutiny when entering into
arrangements with Telemedicine
Companies that have one or more of the
suspect characteristics described below.
This Special Fraud Alert provides
information to help Practitioners
identify potentially suspect
arrangements with Telemedicine
Companies.
II. Multiple Federal Laws Implicated
The schemes described above may
implicate multiple Federal laws,
including the Federal anti kickback
statute. The Federal anti-kickback
statute is a criminal law that prohibits
knowingly and willfully soliciting or
receiving (or offering or paying) any
remuneration in return for (or to
induce), among other things, referrals
for, or orders of, items or services
reimbursable by a Federal health care
program. One purpose of the Federal
anti-kickback statute is to protect
patients from improper medical referrals
or recommendations by health care
professionals and others who may be
influenced by financial incentives.
E:\FR\FM\23AUN1.SGM
23AUN1
Federal Register / Vol. 87, No. 162 / Tuesday, August 23, 2022 / Notices
When a party knowingly and willfully
pays remuneration to induce or reward
referrals of items or services payable by
a Federal health care program, the
Federal anti-kickback statute is violated.
By its terms, the statute ascribes liability
to parties on both sides of an
impermissible kickback transaction.
Practitioner arrangements with
Telemedicine Companies may also lead
to criminal, civil, or administrative
liability under other Federal laws
including, for example, OIG’s exclusion
authority related to kickbacks, the Civil
Monetary Penalties Law provision for
kickbacks, the criminal health care
fraud statute, and the False Claims Act.
Practitioners may be personally liable
for these types of arrangements,
including for submitting or causing the
submission of claims if they are
involved in ordering or prescribing
medically unnecessary items or
services.
lotter on DSK11XQN23PROD with NOTICES1
III. Recent Enforcement Experience
In recent years, OIG and the
Department of Justice (DOJ) have
investigated numerous criminal, civil,
and administrative fraud cases
involving kickbacks from Telemedicine
Companies to Practitioners who
inappropriately ordered or prescribed
items or services reimbursable by
Federal health care programs in
exchange for remuneration. In those
cases, Practitioners, Telemedicine
Companies, and other participants in
schemes have been held civilly,
criminally, and administratively liable
for: (1) paying or receiving a payment in
violation of the Federal anti-kickback
statute, (2) causing a submission of
claims in violation of the False Claims
Act, and/or (3) other Federal criminal
laws.
While the facts and circumstances of
each case differed, often they involved
at least one Practitioner ordering or
prescribing items or services for
purported patients they never examined
or meaningfully assessed to determine
the medical necessity of items or
services ordered or prescribed. In
addition, Telemedicine Companies
commonly paid Practitioners a fee that
correlated with the volume of federally
reimbursable items or services ordered
or prescribed by the Practitioners,
which was intended to and did
incentivize a Practitioner to order
medically unnecessary items or
services. These types of volume-based
fees not only implicate and potentially
violate the Federal anti-kickback statute,
but they also may corrupt medical
decision-making, drive inappropriate
utilization, and result in patient harm.
VerDate Sep<11>2014
18:53 Aug 22, 2022
Jkt 256001
IV. Suspect Characteristics
Based on OIG’s and DOJ’s
enforcement experience, we have
developed the below list of suspect
characteristics related to Practitioner
arrangements with Telemedicine
Companies which, taken together or
separately, could suggest an
arrangement that presents a heightened
risk of fraud and abuse. This list is
illustrative, not exhaustive, and the
presence or absence of any one of these
factors is not determinative of whether
a particular arrangement with a
Telemedicine Company would be
grounds for legal sanctions.
• The purported patients for whom
the Practitioner orders or prescribes
items or services were identified or
recruited by the Telemedicine
Company, telemarketing company, sales
agent, recruiter, call center, health fair,
and/or through internet, television, or
social media advertising for free or low
out-of-pocket cost items or services.
• The Practitioner does not have
sufficient contact with or information
from the purported patient to
meaningfully assess the medical
necessity of the items or services
ordered or prescribed.
• The Telemedicine Company
compensates the Practitioner based on
the volume of items or services ordered
or prescribed, which may be
characterized to the Practitioner as
compensation based on the number of
purported medical records that the
Practitioner reviewed.
• The Telemedicine Company only
furnishes items and services to Federal
health care program beneficiaries and
does not accept insurance from any
other payor.
• The Telemedicine Company claims
to only furnish items and services to
individuals who are not Federal health
care program beneficiaries but may in
fact bill Federal health care programs.
• The Telemedicine Company only
furnishes one product or a single class
of products (e.g., durable medical
equipment, genetic testing, diabetic
supplies, or various prescription
creams), potentially restricting a
Practitioner’s treating options to a
predetermined course of treatment.
• The Telemedicine Company does
not expect Practitioners (or another
Practitioner) to follow up with
purported patients nor does it provide
Practitioners with the information
required to follow up with purported
patients (e.g., the Telemedicine
Company does not require Practitioners
to discuss genetic testing results with
each purported patient).
Practitioners who enter into
arrangements with Telemedicine
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
51687
Companies in which one or more of
these suspect characteristics are present
should exercise care and may face
criminal, civil, or administrative
liability depending on the facts and
circumstances. This Special Fraud Alert
is not intended to discourage legitimate
telehealth arrangements. For example,
OIG is aware that many Practitioners
have appropriately used telehealth
services during the current public
health emergency to provide medically
necessary care to their patients.
However, OIG encourages Practitioners
to use heightened scrutiny, exercise
caution, and consider the above list of
suspect criteria prior to entering into
arrangements with Telemedicine
Companies. This Special Fraud Alert
does not alter any person’s obligations
under any applicable statutes or
regulations, including those governing
the billing or submission of Federal
health care program claims.
For more information on telehealthrelated issues, please visit our website,
which includes additional materials
relating to the provision of telehealth. If
you have information about
Practitioners, Telemedicine Companies,
or other individuals or entities engaging
in any of the activities described above,
please contact the OIG Hotline at
https://oig.hhs.gov/fraud/report-fraud or
by phone at 1–800–447–8477 (1–800–
HHS–TIPS).
Dated: August 17, 2022.
Gregory D. Demske,
Acting Principal Deputy Inspector General.
[FR Doc. 2022–18063 Filed 8–22–22; 8:45 am]
BILLING CODE 4150–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Diabetes and
Digestive and Kidney Diseases Advisory
Council, September 07, 2022, 10:00 a.m.
to September 08, 2022, 2:00 p.m.,
National Institutes of Health, Building
31, 31 Center Drive, Bethesda, MD
20892 which was published in the
Federal Register on December 29, 2021,
304543.
The meeting notice is amended to
change and adjust the format of the
meeting from Regular to Video Assisted
Meeting. The meeting is partially closed
to the public.
E:\FR\FM\23AUN1.SGM
23AUN1
Agencies
[Federal Register Volume 87, Number 162 (Tuesday, August 23, 2022)]
[Notices]
[Pages 51683-51687]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18063]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of Inspector General
Publication of OIG Special Fraud Alerts
AGENCY: Office of Inspector General (OIG), HHS.
[[Page 51684]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This Federal Register notice sets forth two Special Fraud
Alerts previously published by OIG on its website. We are publishing
these Special Fraud Alerts in the Federal Register to ensure widespread
dissemination of the Special Fraud Alerts to the general public and to
satisfy the Federal Register publication requirement.
FOR FURTHER INFORMATION CONTACT: Katie Fink, Karen Glassman, or
Benjamin Wallfisch, (202) 619-0335.
I. Background
Pursuant to 42 U.S.C. 1320a-7d(c), OIG periodically issues Special
Fraud Alerts to give continuing guidance to health care industry
stakeholders regarding practices OIG considers to be suspect or of
particular concern. Special Fraud Alerts encourage industry compliance
by giving stakeholders guidance that can be applied to their own
practices. In developing Special Fraud Alerts, OIG relies on several
sources and consults directly with experts in the subject field
including those within OIG, other HHS agencies, other Federal and State
agencies, and in the health care industry.
To ensure widespread dissemination of this information to the
general public and to satisfy the Federal Register publication
requirement found in 42 U.S.C. 1320a-7d(c)(1)(B), OIG is republishing
two Special Fraud Alerts--in their entirety--below. These Special Fraud
Alerts are: (1) Special Fraud Alert: Speaker Programs, which was
originally published on OIG's website on November 16, 2020; and (2)
Special Fraud Alert: OIG Alerts Practitioners To Exercise Caution When
Entering Into Arrangements With Purported Telemedicine Companies, which
was originally published on OIG's website on July 20, 2022.
II. Special Fraud Alert: Speaker Programs
I. Introduction
This Special Fraud Alert highlights the fraud and abuse risks
associated with the offer, payment, solicitation, or receipt of
remuneration relating to speaker programs by pharmaceutical and medical
device companies. For purposes of this Special Fraud Alert, speaker
programs are generally defined as company-sponsored events at which a
physician or other health care professional (collectively, ``HCP'')
makes a speech or presentation to other HCPs about a drug or device
product or a disease state on behalf of the company. The company
generally pays the speaker HCP an honorarium, and often pays
remuneration (for example, free meals) to the attendees. In the last
three years, drug and device companies have reported paying nearly $2
billion to HCPs for speaker-related services.\1\
---------------------------------------------------------------------------
\1\ Drug and device companies are required to report certain
payments made to HCPs to the Centers for Medicare & Medicaid
Services (CMS). CMS makes this information publicly available on its
Open Payments website. According to Open Payments, drug and device
companies paid HCPs nearly $2 billion under the category
``compensation for services other than consulting, including serving
as faculty or as a speaker at a venue other than a continuing
education program'' for years 2017, 2018, and 2019 combined. Open
Payments Complete 2017, 2018, and 2019 Program Year Datasets, CMS,
https://www.cms.gov/OpenPayments/Explore-the-Data/Data-Overview
(accessed Sept. 9, 2020).
---------------------------------------------------------------------------
The Office of Inspector General (OIG) and Department of Justice
(DOJ) have investigated and resolved numerous fraud cases involving
allegations that remuneration offered and paid in connection with
speaker programs violated the anti-kickback statute. The Federal
government has pursued civil and criminal cases against companies and
individual HCPs involving speaker programs. These cases alleged, for
example, that drug and device companies:
selected high-prescribing HCPs to be speakers and rewarded
them with lucrative speaker deals (e.g., some HCPs received hundreds of
thousands of dollars for speaking); \2\
---------------------------------------------------------------------------
\2\ Though not addressed in this Special Fraud Alert,
remuneration paid by drug and device companies relating to the
training of HCP speakers also may raise fraud and abuse risks.
---------------------------------------------------------------------------
conditioned speaker remuneration on sales targets (e.g.,
required speaker HCPs to write a minimum number of prescriptions in
order to receive the speaker honoraria);
held speaker programs at entertainment venues or during
recreational events or otherwise in a manner not conducive to an
educational presentation (e.g., wineries, sports stadiums, fishing
trips, golf clubs, and adult entertainment facilities);
held programs at high-end restaurants where expensive
meals and alcohol were served (e.g., in one case, the average food and
alcohol cost per attendee was over $500); and
invited an audience of HCP attendees who had previously
attended the same program or HCPs' friends, significant others, or
family members who did not have a legitimate business reason to attend
the program.
Our enforcement experience demonstrates that some companies expend
significant resources on speaker programs and that some HCPs receive
substantial remuneration from companies. This Special Fraud Alert
highlights some of the inherent fraud and abuse risks associated with
the offer, payment, solicitation, or receipt of remuneration related to
company-sponsored speaker programs.
II. The Anti-Kickback Statute
Congress enacted the anti-kickback statute, in part, to protect
patients from referrals or recommendations by HCPs who may be
influenced by inappropriate financial incentives. The anti-kickback
statute makes it a criminal offense to knowingly and willfully solicit,
receive, offer, or pay any remuneration to induce or reward, among
other things, referrals for, or orders of, items or services
reimbursable by a Federal health care program.\3\ When remuneration is
paid purposefully to induce or reward referrals of items or services
payable by a Federal health care program, the anti-kickback statute is
violated. For purposes of the anti-kickback statute, the offer,
payment, solicitation, or receipt of ``remuneration'' includes the
transfer of anything of value, directly or indirectly, overtly or
covertly, in cash or in kind. By its terms, the statute ascribes
criminal liability to all parties to an impermissible ``kickback''
transaction (i.e., those who solicit or receive prohibited remuneration
as well as those who offer or pay the prohibited remuneration).
Violation of the statute is a felony punishable by a maximum fine of
$100,000, imprisonment up to 10 years, or both. Criminal conviction
will also lead to mandatory exclusion from Federal health care
programs, including Medicare and Medicaid.\4\ OIG may also initiate
administrative proceedings to exclude persons from the Federal health
care programs and impose civil money penalties for conduct prohibited
by the anti-kickback statute.\5\
---------------------------------------------------------------------------
\3\ See section 1128B(b)(1)-(2) of the Social Security Act; 42
U.S.C. 1320a-7b(b)(1)-(2). The anti-kickback statute applies broadly
to remuneration to induce or reward referrals of patients as well as
the payment of remuneration intended to induce or reward the
purchasing, leasing, or ordering of, or arranging for or
recommending the purchasing, leasing, or ordering of, any item or
service reimbursable by any Federal health care program. In this
Special Fraud Alert, we use the term ``referral'' to include the
full range of these types of activities (including ordering or
prescribing items) that falls within the scope of the anti-kickback
statute.
\4\ See 42 U.S.C. 1320a-7(a).
\5\ See 42 U.S.C. 1320a-7(b)(7); 1320a-7a(a)(7).
---------------------------------------------------------------------------
III. Fraud and Abuse Risks of Speaker Programs
Numerous investigations have involved allegations that drug and
device companies organize and pay for speaker programs with the intent
to
[[Page 51685]]
induce HCPs to prescribe or order (or recommend the prescription or
ordering of) the companies' products. Speaker programs typically
involve an HCP who is not an employee of the company speaking in person
to other HCPs about a company product or disease state using a
presentation developed and approved by the company. According to a
pharmaceutical industry trade group, HCPs ``participate in company-
sponsored speaker programs in order to help educate and inform other
health care professionals about the benefits, risks, and appropriate
uses of company medicines.'' \6\
---------------------------------------------------------------------------
\6\ Code on Interactions with Health Care Professionals, PhRMA,
7 (June 2020), available at https://phrma.org/Codes-and-guidelines/Code-on-Interactions-with-Health-Care-Professionals. A device
industry trade group also addresses this topic and interactions with
HCPs generally in its code of ethics. See AdvaMed Code of Ethics,
AdvaMed (July 2020), available at https://www.advamed.org/resource-center/advamed-code-ethics-2020.
---------------------------------------------------------------------------
OIG is skeptical about the educational value of such programs. Our
investigations have revealed that, often, HCPs receive generous
compensation to speak at programs offered under circumstances that are
not conducive to learning or to speak to audience members who have no
legitimate reason to attend. Such cases strongly suggest that one
purpose of the remuneration to the HCP speaker and attendees is to
induce or reward referrals. Furthermore, studies have shown that HCPs
who receive remuneration from a company are more likely to prescribe or
order that company's products.\7\ This remuneration to HCPs may skew
their clinical decision making in favor of their own and the company's
financial interests, rather than the patient's best interests.
---------------------------------------------------------------------------
\7\ Amarnath Annapureddy et al., Association Between Industry
Payments to Physicians and Device Selection in ICD Implantation, 324
JAMA 17, 2020, at 1759, 1762-63; William Fleischman et al.,
Association between payments from manufacturers of pharmaceuticals
to physicians and regional prescribing: cross sectional ecological
study, 354 BMJ i4189, 2016, at 1, 4-7; James P. Orlowski & Leon
Wateska, The effects of pharmaceutical firm enticements on physician
prescribing patterns. There's no such thing as a free lunch., 102
Chest, 1992, 270.
---------------------------------------------------------------------------
There are many other ways for HCPs to obtain information about drug
and device products and disease states that do not involve remuneration
to HCPs. HCPs can access the same or similar information provided in a
speaker program using various online resources, the product's package
insert, third-party educational conferences, medical journals, and
more. The availability of this information through means that do not
involve remuneration to HCPs further suggests that at least one purpose
of remuneration associated with speaker programs is often to induce or
reward referrals.
Parties involved in speaker programs may be subject to increased
scrutiny. These include any drug or device company that organizes or
pays remuneration associated with the program, any HCP who is paid to
speak, and any HCP attendees who receive remuneration from the company
(e.g., free food and drink). OIG has long expressed concerns over the
practice of drug and device companies providing anything of value to
HCPs in a position to make or influence referrals to such companies'
products. In the 2003 OIG Compliance Program Guidance for
Pharmaceutical Manufacturers,\8\ OIG identified manufacturer
compensation relationships with physicians connected directly or
indirectly to marketing and sales activities, including speaking
activities, as an area of potential risk under the anti-kickback
statute. OIG noted that when a drug or device company engages in
``entertainment, recreation, travel, meals or other benefits in
association with information or marketing presentations,'' such
arrangements may potentially implicate the anti-kickback statute.\9\
---------------------------------------------------------------------------
\8\ OIG Compliance Program Guidance for Pharmaceutical
Manufacturers, 68 FR 23731 (May 5, 2003), available at https://oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf. The guidance
is not limited to pharmaceutical manufacturers; it states, ``the
compliance program elements and potential risk areas addressed in
this compliance program guidance may also have application to
manufacturers of other products that may be reimbursed by [F]ederal
health care programs, such as medical devices and infant nutritional
products.'' Id. at 23742, n.5.
\9\ Id. at 23738.
---------------------------------------------------------------------------
OIG also warned physicians that a consultant or speaking
arrangement with a drug or device company could be an improper
inducement ``to prescribe or use [company] products on the basis of . .
. loyalty to the company or to get more money from the company, rather
than because it is the best treatment for the patient.'' \10\ OIG
recommended that physicians consider the propriety of any proposed
relationship with a company and advised that if the basis for a
physician's compensation ``is your ability to prescribe a drug or use a
medical device or refer your patients for particular services or
supplies, the proposed consulting arrangement likely is one you should
avoid as it could violate fraud and abuse laws.'' \11\ Again, we note
that HCPs could face liability under the anti-kickback statute for
knowingly and willfully soliciting or receiving remuneration in
connection with speaker programs in return for prescribing or ordering
products reimbursable by a Federal health care program.
---------------------------------------------------------------------------
\10\ A Roadmap for New Physicians, Avoiding Medicare and
Medicaid Fraud and Abuse, HHS-OIG, 22 (Nov. 2010), available at
https://oig.hhs.gov/compliance/physician-education/roadmap_web_version.pdf; OIG Compliance Program for Individual and
Small Group Physician Practices, 65 FR 59434 (Oct. 5, 2000),
available at https://oig.hhs.gov/authorities/docs/physician.pdf.
\11\ Id. at 23.
---------------------------------------------------------------------------
OIG recognizes that the lawfulness of any remunerative arrangement,
including speaker program arrangements, under the anti-kickback statute
depends on the facts and circumstances and intent of the parties. Such
intent may be evidenced by the speaker program's characteristics and
the actual conduct of the parties involved. Below we describe some
characteristics, which, taken separately or together, potentially
indicate a speaker program arrangement that could violate the anti-
kickback statute. As previously stated, drug and device companies that
host or pay for such speaker programs and HCPs who speak at or attend
such programs could be liable under the anti-kickback statute for any
prohibited remuneration. This list of suspect characteristics is
illustrative, not exhaustive, and the presence or absence of any one of
these factors is not determinative of whether a particular arrangement
would be suspect under the anti-kickback statute.
The company sponsors speaker programs where little or no
substantive information is actually presented;
Alcohol is available or a meal exceeding modest value is
provided to the attendees of the program (the concern is heightened
when the alcohol is free);
The program is held at a location that is not conducive to
the exchange of educational information (e.g., restaurants or
entertainment or sports venues);
The company sponsors a large number of programs on the
same or substantially the same topic or product, especially in
situations involving no recent substantive change in relevant
information;
There has been a significant period of time with no new
medical or scientific information nor a new FDA-approved or cleared
indication for the product;
HCPs attend programs on the same or substantially the same
topics more than once (as either a repeat attendee or as an attendee
after being a speaker on the same or substantially the same topic);
Attendees include individuals who don't have a legitimate
business reason
[[Page 51686]]
to attend the program, including, for example, friends, significant
others, or family members of the speaker or HCP attendee; employees or
medical professionals who are members of the speaker's own medical
practice; staff of facilities for which the speaker is a medical
director; and other individuals with no use for the information;
The company's sales or marketing business units influence
the selection of speakers or the company selects HCP speakers or
attendees based on past or expected revenue that the speakers or
attendees have or will generate by prescribing or ordering the
company's product(s) (e.g., a return on investment analysis is
considered in identifying participants);
The company pays HCP speakers more than fair market value
for the speaking service or pays compensation that takes into account
the volume or value of past business generated or potential future
business generated by the HCPs.
IV. Conclusion
OIG has significant concerns about companies offering or paying
remuneration (and HCPs soliciting or receiving remuneration) in
connection with speaker programs. Based on our investigations and
enforcement actions, this remuneration is often offered or paid to
induce (or solicited or received in return for) ordering or prescribing
items paid for by Federal health care programs. If the requisite intent
is present, both the company and the HCPs may be subject to criminal,
civil, and administrative enforcement actions. This Special Fraud Alert
is not intended to discourage meaningful HCP training and education.
Rather, the purpose of this Special Fraud Alert is to highlight certain
inherent risks of remuneration related to speaker programs. Drug and
device companies and HCPs should consider the risks when assessing
whether to offer, pay, solicit, or receive remuneration related to
speaker programs.
We are issuing this alert during the pandemic emergency, which is
necessarily curtailing many in-person activities. While companies may
have decreased in-person speaker program-related remuneration to HCPs
during the pandemic, risks remain whenever payments are offered or made
to HCPs who generate Federal health care program business for the
company. The risks associated with speaker programs will become more
pronounced if companies resume in-person speaker programs or increase
speaker program-related remuneration to HCPs. Companies should assess
the need for in-person programs given the risks associated with
offering or paying related remuneration and consider alternative less-
risky means for conveying information to HCPs. HCPs should likewise
consider the risks of soliciting or receiving remuneration related to
speaker programs given other available means to gather information
relevant to providing appropriate treatment for patients. If a company
or HCP has questions about a specific speaker program arrangement
involving remuneration to referral sources, the OIG Advisory Opinion
process remains available. Information about that process may be found
at: https://oig.hhs.gov/faqs/advisory-opinions-faq.asp.
III. Special Fraud Alert: OIG Alerts Practitioners To Exercise Caution
When Entering Into Arrangements With Purported Telemedicine Companies
I. Introduction
The Office of Inspector General (OIG) has conducted dozens of
investigations of fraud schemes involving companies that purported to
provide telehealth, telemedicine, or telemarketing services
(collectively, Telemedicine Companies) and exploited the growing
acceptance and use of telehealth. For example, in some of these fraud
schemes Telemedicine Companies intentionally paid physicians and
nonphysician practitioners (collectively, Practitioners) kickbacks to
generate orders or prescriptions for medically unnecessary durable
medical equipment, genetic testing, wound care items, or prescription
medications, resulting in submissions of fraudulent claims to Medicare,
Medicaid, and other Federal health care programs. These fraud schemes
vary in design and operation, and they have involved a wide range of
different individuals and types of entities, including international
and domestic telemarketing call centers, staffing companies,
Practitioners, marketers, brokers, and others.
One common element of these schemes is the way Telemedicine
Companies have used kickbacks to aggressively recruit and reward
Practitioners to further the fraud schemes. Generally, the Telemedicine
Companies arrange with Practitioners to order or prescribe medically
unnecessary items and services for individuals (referred to here as
``purported patients'') who are solicited and recruited by Telemedicine
Companies. In many of these arrangements, Telemedicine Companies pay
Practitioners in exchange for ordering or prescribing items or
services: (1) for purported patients with whom the Practitioners have
limited, if any, interaction; and (2) without regard to medical
necessity. Such payments are sometimes described as payment per review,
audit, consult, or assessment of medical charts. Telemedicine Companies
often tell Practitioners that they do not need to contact the purported
patient or that they only need speak to the purported patient by
telephone. In addition, Practitioners are not given an opportunity to
review the purported patient's real medical records. Furthermore, the
Telemedicine Company may direct Practitioners to order or prescribe a
preselected item or service, regardless of medical necessity or
clinical appropriateness. In many cases, the Telemedicine Company sells
the order or prescription generated by Practitioners to other
individuals or entities that then fraudulently bill for the unnecessary
items and services.
These schemes raise fraud concerns because of the potential for
considerable harm to Federal health care programs and their
beneficiaries, which may include: (1) an inappropriate increase in
costs to Federal health care programs for medically unnecessary items
and services and, in some instances, items and services a beneficiary
never receives; (2) potential to harm beneficiaries by, for example,
providing medically unnecessary care, items that could harm a patient,
or improperly delaying needed care; and (3) corruption of medical
decision-making.
OIG encourages Practitioners to exercise caution and use heightened
scrutiny when entering into arrangements with Telemedicine Companies
that have one or more of the suspect characteristics described below.
This Special Fraud Alert provides information to help Practitioners
identify potentially suspect arrangements with Telemedicine Companies.
II. Multiple Federal Laws Implicated
The schemes described above may implicate multiple Federal laws,
including the Federal anti kickback statute. The Federal anti-kickback
statute is a criminal law that prohibits knowingly and willfully
soliciting or receiving (or offering or paying) any remuneration in
return for (or to induce), among other things, referrals for, or orders
of, items or services reimbursable by a Federal health care program.
One purpose of the Federal anti-kickback statute is to protect patients
from improper medical referrals or recommendations by health care
professionals and others who may be influenced by financial incentives.
[[Page 51687]]
When a party knowingly and willfully pays remuneration to induce or
reward referrals of items or services payable by a Federal health care
program, the Federal anti-kickback statute is violated. By its terms,
the statute ascribes liability to parties on both sides of an
impermissible kickback transaction. Practitioner arrangements with
Telemedicine Companies may also lead to criminal, civil, or
administrative liability under other Federal laws including, for
example, OIG's exclusion authority related to kickbacks, the Civil
Monetary Penalties Law provision for kickbacks, the criminal health
care fraud statute, and the False Claims Act. Practitioners may be
personally liable for these types of arrangements, including for
submitting or causing the submission of claims if they are involved in
ordering or prescribing medically unnecessary items or services.
III. Recent Enforcement Experience
In recent years, OIG and the Department of Justice (DOJ) have
investigated numerous criminal, civil, and administrative fraud cases
involving kickbacks from Telemedicine Companies to Practitioners who
inappropriately ordered or prescribed items or services reimbursable by
Federal health care programs in exchange for remuneration. In those
cases, Practitioners, Telemedicine Companies, and other participants in
schemes have been held civilly, criminally, and administratively liable
for: (1) paying or receiving a payment in violation of the Federal
anti-kickback statute, (2) causing a submission of claims in violation
of the False Claims Act, and/or (3) other Federal criminal laws.
While the facts and circumstances of each case differed, often they
involved at least one Practitioner ordering or prescribing items or
services for purported patients they never examined or meaningfully
assessed to determine the medical necessity of items or services
ordered or prescribed. In addition, Telemedicine Companies commonly
paid Practitioners a fee that correlated with the volume of federally
reimbursable items or services ordered or prescribed by the
Practitioners, which was intended to and did incentivize a Practitioner
to order medically unnecessary items or services. These types of
volume-based fees not only implicate and potentially violate the
Federal anti-kickback statute, but they also may corrupt medical
decision-making, drive inappropriate utilization, and result in patient
harm.
IV. Suspect Characteristics
Based on OIG's and DOJ's enforcement experience, we have developed
the below list of suspect characteristics related to Practitioner
arrangements with Telemedicine Companies which, taken together or
separately, could suggest an arrangement that presents a heightened
risk of fraud and abuse. This list is illustrative, not exhaustive, and
the presence or absence of any one of these factors is not
determinative of whether a particular arrangement with a Telemedicine
Company would be grounds for legal sanctions.
The purported patients for whom the Practitioner orders or
prescribes items or services were identified or recruited by the
Telemedicine Company, telemarketing company, sales agent, recruiter,
call center, health fair, and/or through internet, television, or
social media advertising for free or low out-of-pocket cost items or
services.
The Practitioner does not have sufficient contact with or
information from the purported patient to meaningfully assess the
medical necessity of the items or services ordered or prescribed.
The Telemedicine Company compensates the Practitioner
based on the volume of items or services ordered or prescribed, which
may be characterized to the Practitioner as compensation based on the
number of purported medical records that the Practitioner reviewed.
The Telemedicine Company only furnishes items and services
to Federal health care program beneficiaries and does not accept
insurance from any other payor.
The Telemedicine Company claims to only furnish items and
services to individuals who are not Federal health care program
beneficiaries but may in fact bill Federal health care programs.
The Telemedicine Company only furnishes one product or a
single class of products (e.g., durable medical equipment, genetic
testing, diabetic supplies, or various prescription creams),
potentially restricting a Practitioner's treating options to a
predetermined course of treatment.
The Telemedicine Company does not expect Practitioners (or
another Practitioner) to follow up with purported patients nor does it
provide Practitioners with the information required to follow up with
purported patients (e.g., the Telemedicine Company does not require
Practitioners to discuss genetic testing results with each purported
patient).
Practitioners who enter into arrangements with Telemedicine
Companies in which one or more of these suspect characteristics are
present should exercise care and may face criminal, civil, or
administrative liability depending on the facts and circumstances. This
Special Fraud Alert is not intended to discourage legitimate telehealth
arrangements. For example, OIG is aware that many Practitioners have
appropriately used telehealth services during the current public health
emergency to provide medically necessary care to their patients.
However, OIG encourages Practitioners to use heightened scrutiny,
exercise caution, and consider the above list of suspect criteria prior
to entering into arrangements with Telemedicine Companies. This Special
Fraud Alert does not alter any person's obligations under any
applicable statutes or regulations, including those governing the
billing or submission of Federal health care program claims.
For more information on telehealth-related issues, please visit our
website, which includes additional materials relating to the provision
of telehealth. If you have information about Practitioners,
Telemedicine Companies, or other individuals or entities engaging in
any of the activities described above, please contact the OIG Hotline
at https://oig.hhs.gov/fraud/report-fraud or by phone at 1-800-447-8477
(1-800-HHS-TIPS).
Dated: August 17, 2022.
Gregory D. Demske,
Acting Principal Deputy Inspector General.
[FR Doc. 2022-18063 Filed 8-22-22; 8:45 am]
BILLING CODE 4150-01-P